First human gets new antibody aimed at rabies virus Oct 1, 2009
To address the supply problems and side-effect issues, MassBiologics and the U.S. Centers for Disease Control and Prevention launched an effort to develop a MAB that could be used in place of hRIG. The research used, in part, HuMab mice from Medarex, Inc. (Princeton, N.J.) which are transgenic mice able to produce fully human antibodies. Pre-clinical testing of the new MAB showed that it neutralized all isolates available from a panel of rabies viruses. (EurekAlert!)
GENova Biotherapeutics signs LOI with Korean university for stem cell research and patents sharing Sep 18, 2009
The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at. (PR Newswire)
GENova appoints Dr. Philip Gould to Scientific Advisory Board Sep 14, 2009
The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer (NYSE: ), Amgen (Nasdaq: ), Myriad Genetics (Nasdaq: ), Medarex (Nasdaq: ), and Biogen Idec (Nasdaq: ). Visit GENova online at. (PR Newswire)
GENova names Aaron Whiteman as CEO Aug 19, 2009
He has previously worked with companies such as Pfizer (NYSE: ), Amgen (Nasdaq: ), Myriad Genetics (Nasdaq: ), Medarex (Nasdaq: ), and Biogen Idec (Nasdaq: ). Mr. Whiteman said, "I am excited to provide the executive leadership to take GENova to its next stage of growth in this crucial phase of commercializing GENova's technology in the marketplace.". (PR Newswire)
3 Ridiculously Cheap, High-Quality Companies Aug 7, 2009
A closer look at Bristol-Myers SquibbBristol-Myers Squibb recently agreed to purchaseMedarex (Nasdaq: MEDX), renewing excitement over its pipeline ... Bristol-Myers Squibb] is purchasing Medarex who has a wonderful potential blockbuster drug in Ipilimumab ... Medarex has forty other compounds in various stages of development and [Bristol-Myers Squibb] can utilize their financial strength to bring them forward. (MSNBC -- Business)
Investor tips for decoding medical journal studies Aug 5, 2009
In one recent example, shares of drug developer Medarex Inc. opened up nearly 21 percent on June 22 after a report that tumors shrank dramatically in just two men in a study of its experimental prostate cancer drug ... Then shares doubled at the opening bell on July 23 on news the night before that Bristol-Myers Squibb Co. is buying Medarex for nearly double the prior stock price. (NJ.com -- News)
Harwood Feffer LLP Files Class Action On Behalf of Shareholders of Medarex, Inc. -- MEDX Aug 1, 2009
NEW YORK, July 31, 2009 (GLOBE NEWSWIRE) -- The law firm of Harwood Feffer LLP announces that it filed a Federal class action lawsuit on July 31, 2009 on behalf of the current shareholders of the common stock of Medarex, Inc. (the "Company") (Nasdaq: - ) in connection with a tender offer by Bristol-Myers Squibb Company. Medarex shareholders may obtain a copy of the complaint by calling our offices or emailing us at the e-mail addresses listed below ... The complaint alleges that defendants... (Primezone Releases)
10 Stocks Shaking the Market Jul 30, 2009
Medarex (Nasdaq: MEDX) ... Unless a bidding war breaks out, as CAPS All-Star member Vavoom11 notes, it's probably too late for investors to realize much upside in Medarex, after Bristol-Myers Squibb (NYSE: BMY) offered a 90% premium to buy the company. (MSNBC -- Business)
Bristol-Myers Squibb Bets Big on a Mouse Jul 24, 2009
The pharmaceutical giant paid top dollar for Medarex, which developed mice with human-like immune systems that may be key to drug R&D ... On July 22, the New York pharmaceutical giant announced that it would buy Medarex () for $2 ... Medarex's claim to fame is UltiMAb, a mouse with a human immune system, which allows it to produce disease-fighting antibodies in its cells. (BusinessWeek)
After Medarex buy, biotech investors ask who's next Jul 24, 2009
After Medarex buy, biotech investors ask who's next - Yahoo ... After Medarex buy, biotech investors ask who's next ... NEW YORK (Reuters) Investors bid up shares of Regeneron Pharmaceuticals Inc (REGN.O) and Seattle Genetics Inc (SGEN.O) on Thursday after Medarex Inc (MEDX.O) agreed to be acquired by Bristol-Myers Squibb Co (BMY.N) at a 90 percent premium. (Yahoo News -- Pharmaceutical Industry News)
* Bristol-Myers Squibb buying Medarex Jul 24, 2009
Bristol-Myers Squibb buying Medarex ... Bristol-Myers Squibb Co said on Wednesday it was buying Medarex Inc for about US$2 ... New York-based Bristol-Myers said it would pay US$16 a share for Medarex, based in Princeton, New Jersey. (Taipei Times, Taiwan -- World Business)
Welcome Back to 9000; Dow Sets New Jul 24, 2009
Existing users please login. Remember me on this computer. (Fox News)
Stocks rally on home sales report as Dow tops 9,000 Jul 24, 2009
The company said it will pay $16 a share for Medarex a 90% premium over Medarex's closing share price Wednesday. Meanwhile, Amazon. (USA Today -- Money)
Dow closes above 9,000 with 188-point rise Jul 24, 2009
Bristol-Myers Squibb Co. said it plans to acquire Medarex Inc. for about $2. 1 billion, the latest in a string of acquisitions by the drug maker. (Crain's Chicago Business)
Stocks Rally, with Dow Topping 9,000 Jul 24, 2009
Shares of Medarex () jumped after Bristol-Myers Squibb () agreed to acquire the biotech firm for $16 per share in cash, or an aggregate price of $2. 4 billion. (BusinessWeek)
Bristol-Myers Q2 Profit Up 29% on Higher Sales Jul 24, 2009
The news comes a day after Bristol agreed to acquire partner Medarex Inc. (MEDX) in a $2. 1 billion deal that would give the company access to a promising cancer treatment, in another move by the company to strategize for the loss of patent protection of Plavix. (SmartMoney)
Bristol-Myers to buy Medarex for $2.4 billion Jul 23, 2009
Bristol-Myers to buy Medarex for $2 ... Bristol-Myers to buy Medarex for $2 ... 4 billion to acquire Medarex Inc (MEDX.O), a biotechnology company that has been helping it develop a promising treatment for melanoma since 2005. (Yahoo News -- Press Releases)
Bristol Myers buying Medarex for $2.1 billion Jul 23, 2009
Bristol Myers buying Medarex for $2 ... Bristol Myers buying Medarex for $2 ... NEW YORK - Drugmaker Bristol-Myers Squibb Co. said Wednesday it is buying Medarex Inc. for about $2. (MSNBC -- Business)
Bristol Myers Says to Buy Medarex for $2.1B Jul 23, 2009
Bristol Myers Says to Buy Medarex for $2 ... Bristol Myers Says to Buy Medarex for $2 ... Drugmaker Bristol-Myers Squibb says to buy Medarex for $2. (ABC News -- Wire)
Roche says half-year profit down 29 percent Jul 23, 2009
Bristol Myers says to buy Medarex for $2 ... Bristol-Myers Squibb Co. said Wednesday it is buying Medarex Inc. for about $2 ... New York-based Bristol-Myers said it will pay $16 a share for Medarex, based in Princeton, N.J. The price represents a 90 percent premium over Medarex's closing share price Wednesday of $8. (Fresno Bee -- Business)
Bristol-Myers Gains Novel Cancer Drugs in $2.4 Billion Deal for Medarex Jul 23, 2009
4 Billion Medarex Deal - Bloomberg ... 4 Billion Medarex Deal ... 40 a share for Princeton, New Jersey-based Medarex, the companies said in a statement. (Bloomberg)
$2.1B drug buyout: Bristol-Myers set to acquire Medarex Jul 23, 2009
1B drug buyout: Bristol-Myers set to acquire Medarex - USATODAY.com ... 1B drug buyout: Bristol-Myers set to acquire Medarex ... NEW YORK (AP) Bristol-Myers Squibb said Wednesday it is buying Medarex for about $2. (USA Today -- Money)
Dramatic Outcomes In Prostate Cancer Study Jun 22, 2009
Medarex, Inc. provided the study drug free of charge and supported safety monitoring during the protocol. Adapted from materials provided by. (Science Daily)
Novel antibody prevents infection by hepatitis C virus May 6, 2009
In the current study, MBL scientists injected transgenic mice (HuMAb Mouse technology, Medarex, Inc.) with elements of HCV and then painstakingly searched for individual human antibodies produced in the mice that would recognize and bind to the HCV's outer coat, known as the glycoprotein. Once they found human antibodies that looked promising, they evaluated in vitro the ability of those antibodies to neutralize the virus and selected a lead candidate antibody for further characterization. (EurekAlert!)
